Peter Ganz


Dr. Peter Ganz is the Director of the Center of Excellence in Vascular Research at the Zuckerberg San Francisco General Hospital (ZSFG) and a Professor of Medicine at UCSF. Dr. Ganz served as the Chief of the Cardiovascular Division at ZSFG 2008 – 2019, Dr. Ganz has been a pioneer in translational cardiovascular research. He was the first to publish on vascular endothelial function in health and its dysfunction in atherosclerosis in humans (N Engl J Med 1986; 315:1046-1051). Currently, Dr. Ganz is making important discoveries in the field of proteomics - using modified aptamers as binding reagents to quantify proteins in blood. He is using proteomics to construct prognostic models of disease (JAMA 2016;315:2532-2541) and to understand the biological pathways of diseases and biological mechanisms of drug therapies (Circulation. 2018;137:999–1010).

Dr. Ganz received his M.D. from Harvard, completed his residency at the Massachusetts General Hospital and cardiovascular fellowship at the Brigham and Women’s Hospital. He spent 25 years directing cardiovascular research in the cardiac catheterization laboratories at the Brigham and Women’s Hospital and Harvard Medical School, prior to arriving to UCSF in 2008.
06/1982 - Cardiology Fellowship, Brigham and Women's Hospital
06/1979 - Medical Residency, Massachusetts General Hospital
MD, 06/1976 - Medicine, Harvard Medical School
  1. Proteomics for personalized cardiovascular risk assessment: in pursuit of the Holy Grail.
  2. Impact of Kidney Function on the Blood Proteome and on Protein Cardiovascular Risk Biomarkers in Patients With Stable Coronary Heart Disease.
  3. Mechanisms of Sodium-Glucose Cotransporter 2 Inhibition: Insights From Large-Scale Proteomics.
  4. Does Ambient Ozone or Other Pollutants Modify Effects of Controlled Ozone Exposure on Pulmonary Function?
  5. Nonsurgical Periodontal Therapy in CKD: Findings of the Kidney and Periodontal Disease (KAPD) Pilot Randomized Controlled Trial.
  6. Plasma protein patterns as comprehensive indicators of health.
  7. Emerging Affinity Reagents for High Throughput Proteomics: Trust, but Verify.
  8. William Ganz and His Legacy.
  9. Echocardiographic determination of pulmonary arterial capacitance.
  10. Vascular Aging is Accelerated in Flight Attendants with Occupational Secondhand Smoke Exposure.
  11. Associations of microvascular dysfunction with cardiovascular outcomes: The cardiac, endothelial function and arterial stiffness in ESRD (CERES) cohort.
  12. Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation.
  13. Reproducibility and Variability of Protein Analytes Measured Using a Multiplexed Modified Aptamer Assay.
  14. Proteomic analysis of heart failure hospitalization among patients with chronic kidney disease: The Heart and Soul Study.
  15. Unique Circulating MicroRNA Profiles in HIV Infection.
  16. IL-1ß Inhibition Reduces Atherosclerotic Inflammation in HIV Infection.
  17. Cardiovascular function and ozone exposure: The Multicenter Ozone Study in oldEr Subjects (MOSES).
  18. Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial
  19. Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
  20. Sex differences in vascular dysfunction and cardiovascular outcomes: The cardiac, endothelial function, and arterial stiffness in ESRD (CERES) study.
  21. Association of Arterial and Lymph Node Inflammation With Distinct Inflammatory Pathways in Human Immunodeficiency Virus Infection.
  22. In Reply.
  23. Role of T-Cell Dysfunction, Inflammation, and Coagulation in Microvascular Disease in HIV.
  24. The Kidney and Periodontal Disease (KAPD) study: A pilot randomized controlled trial testing the effect of non-surgical periodontal therapy on chronic kidney disease.
  25. Associations of Macro- and Microvascular Endothelial Dysfunction With Subclinical Ventricular Dysfunction in End-Stage Renal Disease.
  26. Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients With Stable Coronary Heart Disease.
  27. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
  28. Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation.
  29. Continuous transdermal nitroglycerin therapy for menopausal hot flashes: a single-arm, dose-escalation trial.
  30. Endothelin-1 Predicts Hemodynamically Assessed Pulmonary Arterial Hypertension in HIV Infection.
  31. Behavioral Cardiovascular Risk Factors - Effect of Physical Activity and Cardiorespiratory Fitness on Cardiovascular Outcomes.
  32. Soluble endothelial cell selective adhesion molecule and cardiovascular outcomes in patients with stable coronary disease: A report from the Heart and Soul Study.
  33. Association of growth differentiation factor 11/8, putative anti-ageing factor, with cardiovascular outcomes and overall mortality in humans: analysis of the Heart and Soul and HUNT3 cohorts.
  34. Novel Biomarkers of Cardiac Stress, Cardiovascular Dysfunction, and Outcomes in HIV-Infected Individuals.
  35. Traditional Risk Factors Versus Biomarkers for Prediction of Secondary Events in Patients With Stable Coronary Heart Disease: From the Heart and Soul Study.
  36. Correction: A novel minimally-invasive method to sample human endothelial cells for molecular profiling.
  37. Utility of both carotid intima-media thickness and endothelial function for cardiovascular risk stratification in patients with angina-like symptoms.
  38. A novel minimally-invasive method to sample human endothelial cells for molecular profiling.
  39. Depletion of B-cells with rituximab improves endothelial function and reduces inflammation among individuals with rheumatoid arthritis.
  40. Changes in erectile dysfunction over time in relation to Framingham cardiovascular risk in the Boston Area Community Health (BACH) Survey.
  41. Association of peripheral microvascular dysfunction and erectile dysfunction.
  42. Increased levels of asymmetric dimethylarginine are associated with pulmonary arterial hypertension in HIV infection.
  43. Reperfusion times and in-hospital outcomes among patients with an isolated posterior myocardial infarction: insights from the National Cardiovascular Data Registry (NCDR).
  44. All men with vasculogenic erectile dysfunction require a cardiovascular workup.
  45. Role of soluble endothelial cell-selective adhesion molecule biomarker in albuminuria and kidney function changes in patients with coronary artery disease: the Heart and Soul Study.
  46. Physician accuracy in interpreting potential ST-segment elevation myocardial infarction electrocardiograms.
  47. Long-term outcomes of patients sent emergently to the catheterization laboratory for possible primary percutaneous coronary intervention.
  48. Clinical characteristics and reperfusion times among patients with an isolated posterior myocardial infarction.
  49. Emergency medical service utilization and door-to-balloon time for HIV-infected individuals with ST-elevation myocardial infarction.
  50. Endothelial dysfunction in coronary heart disease is more than a systemic process.
  51. Elevated levels of asymmetric dimethylarginine are associated with lower CD4+ count and higher viral load in HIV-infected individuals.
  52. Glycemic associations with endothelial function and biomarkers among 5 ethnic groups: the Multi-Ethnic Study of Atherosclerosis and the Mediators of Atherosclerosis in South Asians Living in America studies.
  53. Comparison of clinical characteristics and outcomes of cardiac arrest survivors having versus not having coronary angiography.
  54. Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study.
  55. Impact of door-to-activation time on door-to-balloon time in primary percutaneous coronary intervention for ST-segment elevation myocardial infarctions: a report from the Activate-SF registry.
  56. The assessment of endothelial function: from research into clinical practice.
  57. Electrocardiographic criteria for ST-elevation myocardial infarction in patients with left ventricular hypertrophy.
  58. Prevalence and factors associated with false-positive ST-segment elevation myocardial infarction diagnoses at primary percutaneous coronary intervention–capable centers: a report from the Activate-SF registry.
  59. Prognostic utility of erectile dysfunction for cardiovascular disease in younger men and those with diabetes.
  60. The association of CD4+ T-cell counts and cardiovascular risk in treated HIV disease.
  61. The exposure-dependent effects of aged secondhand smoke on endothelial function.
  62. Carotid Intima-Media Thickness Progression in HIV-Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by Inflammation.
  63. Delaying primary percutaneous coronary intervention for computed tomographic scans in the emergency department.
  64. Relationship of antihypertensive treatment to plasma markers of vascular inflammation and remodeling in the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis study.
  65. Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy.
  66. Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium.
  67. Improvement in revascularization time after creation of a coronary catheterization laboratory at a public hospital.
  68. Predictors of depressed left ventricular function in patients presenting with ST-elevation myocardial infarction.
  69. Coronary circulatory function in patients with the metabolic syndrome.
  70. The CHADS2 score predicts ischemic stroke in the absence of atrial fibrillation among subjects with coronary heart disease: data from the Heart and Soul Study.
  71. Associations of endothelial dysfunction and arterial stiffness with intradialytic hypotension and hypertension.
  72. High-resolution magnetic resonance imaging enhanced with superparamagnetic nanoparticles measures macrophage burden in atherosclerosis.
  73. AJC editor's consensus: rheumatoid arthritis and atherosclerotic cardiovascular disease.
  74. Initiation of antiretroviral therapy at higher nadir CD4+ T-cell counts is associated with reduced arterial stiffness in HIV-infected individuals.
  75. Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo.
  76. Does erectile dysfunction contribute to cardiovascular disease risk prediction beyond the Framingham risk score?
  77. Assessment of structural disease in the coronary microvasculature.
  78. Association of abacavir and impaired endothelial function in treated and suppressed HIV-infected patients.
  79. Evaluating patients with persistent chest pain and no obstructive coronary artery disease.
  80. Endothelin-1 is a key mediator of coronary vasoconstriction in patients with transplant coronary arteriosclerosis.
  81. Erectile dysfunction and mortality.
  82. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardia
  83. Structural and functional manifestations of human atherosclerosis: do they run in parallel?
  84. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis.
  85. Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis.
  86. Endogenous tissue plasminogen activator and risk of recurrent cardiac events after an acute coronary syndrome in the MIRACL study.
  87. Individualized approach to the management of coronary heart disease: identifying the nonresponders before it is too late.
  88. Comparison of effects of rosuvastatin (10 mg) versus atorvastatin (40 mg) on rho kinase activity in caucasian men with a previous atherosclerotic event.
  89. Statins inhibit Rho kinase activity in patients with atherosclerosis.
  90. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.
  91. Inflammation, statin therapy, and risk of stroke after an acute coronary syndrome in the MIRACL study.
  92. Improved characterization of atherosclerotic plaques by gadolinium contrast during intravascular magnetic resonance imaging of human arteries.
  93. Right ventricular dysfunction assessed by cardiovascular magnetic resonance imaging predicts poor prognosis late after myocardial infarction.
  94. Rho kinase inhibition improves endothelial function in human subjects with coronary artery disease.
  95. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
  96. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans.
  97. Impact of coronary endothelial function on the progression of cardiac transplant-associated arteriosclerosis: effect of anti-oxidant vitamins C and E.
  98. Effect of ACAT inhibition on the progression of coronary atherosclerosis.
  99. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).
  100. Characterization of human atherosclerotic plaques by intravascular magnetic resonance imaging.
  101. Erectile dysfunction: pathophysiologic mechanisms pointing to underlying cardiovascular disease.
  102. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).
  103. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial.
  104. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
  105. Statins and endothelial dysfunction.
  106. Comparison of endothelial function in young men and women with a family history of premature coronary artery disease.
  107. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study.
  108. Role of endothelial dysfunction in atherosclerosis.
  109. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
  110. Long-term effect of combined vitamins E and C on coronary and peripheral endothelial function.
  111. Early statin therapy in acute coronary syndromes.
  112. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
  113. Testing endothelial vasomotor function: nitric oxide, a multipotent molecule.
  114. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study.
  115. Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection.
  116. Endothelin-1 and vascular tone in subjects with atherogenic risk factors.
  117. Oxidized low-density lipoprotein augments and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors limit CD40 and CD40L expression in human vascular cells.
  118. Circulating autoantibodies to oxidized LDL correlate with impaired coronary endothelial function after cardiac transplantation.
  119. Endothelial function. From vascular biology to clinical applications.
  120. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy.
  121. Contribution of endothelin to pulmonary vascular tone under normoxic and hypoxic conditions.
  122. Coronary flow velocity and disturbed flow predict adverse clinical outcome after coronary angioplasty.
  123. Vasomotor and vascular effects of hormone replacement therapy.
  124. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial.